AU2013312113B2 - Composition of HMB and ATP and methods of use - Google Patents

Composition of HMB and ATP and methods of use Download PDF

Info

Publication number
AU2013312113B2
AU2013312113B2 AU2013312113A AU2013312113A AU2013312113B2 AU 2013312113 B2 AU2013312113 B2 AU 2013312113B2 AU 2013312113 A AU2013312113 A AU 2013312113A AU 2013312113 A AU2013312113 A AU 2013312113A AU 2013312113 B2 AU2013312113 B2 AU 2013312113B2
Authority
AU
Australia
Prior art keywords
hmb
atp
animal
strength
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013312113A
Other languages
English (en)
Other versions
AU2013312113A1 (en
Inventor
Shawn Baier
Larry KOLB
John Rathmacher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metabolic Technologies LLC
Original Assignee
Metabolic Technologies LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolic Technologies LLC filed Critical Metabolic Technologies LLC
Publication of AU2013312113A1 publication Critical patent/AU2013312113A1/en
Assigned to TSI, INC., METABOLIC TECHNOLOGIES, INC. reassignment TSI, INC. Amend patent request/document other than specification (104) Assignors: METABOLIC TECHNOLOGIES, INC.
Application granted granted Critical
Publication of AU2013312113B2 publication Critical patent/AU2013312113B2/en
Assigned to Metabolic Technologies, LLC reassignment Metabolic Technologies, LLC Request for Assignment Assignors: Metabolic Technologies, LLC, TSI, INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2013312113A 2012-09-10 2013-09-10 Composition of HMB and ATP and methods of use Active AU2013312113B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261698919P 2012-09-10 2012-09-10
US61/698,919 2012-09-10
PCT/US2013/059039 WO2014040067A1 (en) 2012-09-10 2013-09-10 Composition of hmb and atp and methods of use

Publications (2)

Publication Number Publication Date
AU2013312113A1 AU2013312113A1 (en) 2015-03-26
AU2013312113B2 true AU2013312113B2 (en) 2018-08-02

Family

ID=50237697

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013312113A Active AU2013312113B2 (en) 2012-09-10 2013-09-10 Composition of HMB and ATP and methods of use

Country Status (14)

Country Link
US (1) US10092590B2 (cg-RX-API-DMAC7.html)
EP (2) EP2892522A4 (cg-RX-API-DMAC7.html)
JP (1) JP6258943B2 (cg-RX-API-DMAC7.html)
CN (1) CN105025891B (cg-RX-API-DMAC7.html)
AU (1) AU2013312113B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015005199B1 (cg-RX-API-DMAC7.html)
CA (1) CA2884405C (cg-RX-API-DMAC7.html)
DK (1) DK3733171T3 (cg-RX-API-DMAC7.html)
ES (1) ES2970283T3 (cg-RX-API-DMAC7.html)
FI (1) FI3733171T3 (cg-RX-API-DMAC7.html)
HU (1) HUE065064T2 (cg-RX-API-DMAC7.html)
PL (1) PL3733171T3 (cg-RX-API-DMAC7.html)
PT (1) PT3733171T (cg-RX-API-DMAC7.html)
WO (1) WO2014040067A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018014407A (es) * 2016-05-25 2019-02-21 Tsi Group Ltd Estabilizacion de formulaciones de acido beta-hidroxiisovalerico en capsulas de gel blando.
US10888576B2 (en) * 2018-10-08 2021-01-12 Metabolic Technologies, Inc. Composition of HMB and ATP and methods of use

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050027005A1 (en) * 2003-08-02 2005-02-03 Matthias Boldt Nutrient compositions and methods for sustenance and promotion of positive metabolic energy levels in a targeted manner
US20050261238A1 (en) * 2001-06-04 2005-11-24 Lee Steve S Method for increasing muscle mass and strength through administration of adenosine triphosphate
WO2006034586A1 (en) * 2004-09-29 2006-04-06 Aplodan Formulations Ltd. Nutritional composition for promoting muscle performance and acting as hydrogen (h+) blocker
US20070093553A1 (en) * 2004-03-26 2007-04-26 Baxter Jeffrey H HMB compositions and uses thereof
WO2010068696A1 (en) * 2008-12-09 2010-06-17 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US20120053240A1 (en) * 2009-12-18 2012-03-01 Metabolic Technologies, Inc. Method of Administering beta-hydroxy-beta-methylbutyrate (HMB)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028440A (en) 1990-01-30 1991-07-02 Iowa State University Research Foundation, Inc. Method of raising meat producing animals to increase lean tissue development
US4992470A (en) 1990-02-08 1991-02-12 Iowa State University Research Foundation, Inc. Method of enhancing immune response of mammals
CA2142314C (en) 1992-09-16 1999-06-01 Steven L. Nissen Method of reducing blood levels of total cholesterol and low-density lipoprotein cholesterol
US5348979A (en) 1992-12-23 1994-09-20 Iowa State University Research Foundation Inc. Method of promoting nitrogen retention in humans
US6031000A (en) 1998-06-23 2000-02-29 Iowa State University Research Foundation, Inc. Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
JP4010390B2 (ja) * 1999-09-20 2007-11-21 明治乳業株式会社 免疫賦活化組成物
US20060073891A1 (en) * 2004-10-01 2006-04-06 Holt Timothy M Display with multiple user privacy
KR101299885B1 (ko) * 2005-05-27 2013-08-23 코와 가부시키가이샤 피로 회복을 위한 의약
WO2007108071A1 (ja) * 2006-03-17 2007-09-27 Pharma Foods International Co., Ltd. 抗ストレス組成物及びそれを含有する飲食品
DE102009052640A1 (de) 2009-11-10 2011-05-12 Linde-Lkca-Dresden Gmbh Verfahren und Vorrichtung zur Gaswäsche

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050261238A1 (en) * 2001-06-04 2005-11-24 Lee Steve S Method for increasing muscle mass and strength through administration of adenosine triphosphate
US20050027005A1 (en) * 2003-08-02 2005-02-03 Matthias Boldt Nutrient compositions and methods for sustenance and promotion of positive metabolic energy levels in a targeted manner
US20070093553A1 (en) * 2004-03-26 2007-04-26 Baxter Jeffrey H HMB compositions and uses thereof
WO2006034586A1 (en) * 2004-09-29 2006-04-06 Aplodan Formulations Ltd. Nutritional composition for promoting muscle performance and acting as hydrogen (h+) blocker
WO2010068696A1 (en) * 2008-12-09 2010-06-17 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US20120053240A1 (en) * 2009-12-18 2012-03-01 Metabolic Technologies, Inc. Method of Administering beta-hydroxy-beta-methylbutyrate (HMB)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Gaspari Nutrition - Sizeon, Global New Products Database, Published October 2006, Record ID: 599558 [retreived on 2 August 2017]. Retrieved from the Internet<URL:http://www.gnpd.com/sinatra/recordpage/599558/from_search/SSFK6s8K8V/?page=1> *
Metabolic Technologies NCT01508338 [retrieved on 2 August 2017] Retrieved from the Internet.<URL:https://clinicaltrials.gov/archive/NCT01508338/2012_06_26> *

Also Published As

Publication number Publication date
CA2884405A1 (en) 2014-03-13
EP2892522A1 (en) 2015-07-15
ES2970283T3 (es) 2024-05-27
JP2015527408A (ja) 2015-09-17
EP3733171A1 (en) 2020-11-04
EP2892522A4 (en) 2016-01-20
JP6258943B2 (ja) 2018-01-10
EP3733171B1 (en) 2023-10-25
BR112015005199A2 (pt) 2017-07-04
CA2884405C (en) 2021-03-30
PL3733171T3 (pl) 2024-03-18
CN105025891B (zh) 2020-01-21
BR112015005199B1 (pt) 2022-09-06
DK3733171T3 (da) 2024-01-29
US10092590B2 (en) 2018-10-09
FI3733171T3 (fi) 2024-01-24
AU2013312113A1 (en) 2015-03-26
US20140080781A1 (en) 2014-03-20
HUE065064T2 (hu) 2024-05-28
WO2014040067A1 (en) 2014-03-13
HK1217087A1 (zh) 2016-12-23
CN105025891A (zh) 2015-11-04
PT3733171T (pt) 2024-01-31

Similar Documents

Publication Publication Date Title
Varanoske et al. Effects of β-alanine supplementation and intramuscular carnosine content on exercise performance and health
EP2512236B1 (en) Improved method of administering beta-hydroxy-beta-methylbutyrate (hmb)
JP5762396B2 (ja) 糖尿病療法の支援のためのα−ケト酸を含有する栄養補助剤
CA3087694A1 (en) Compositions and methods of use of .beta.hydroxy-.beta.-methylbutyrate (hmb) associated witth intermittent fasting
Ortiz de Zevallos et al. Sex differences in the effects of inorganic nitrate supplementation on exercise economy and endurance capacity in healthy young adults
US20150366901A1 (en) Methods of Treating Heart Failure
AU2013312113B2 (en) Composition of HMB and ATP and methods of use
US10888576B2 (en) Composition of HMB and ATP and methods of use
US20160184248A1 (en) Compositions and methods of use of -hydroxy-methylbutyrate (hmb) resulting in an acute endocrine response
HK1217087B (zh) Hmb和atp的组合物及使用方法
Arney Mechanisms of Fatigability in Individuals With Prediabetes and the Effect of Dietary Nitrate Supplementation
Ocampo Can We Achieve ‘High-Quality’Weight Loss Through Anabolic and Weight Loss Supplementation in Combination with Exercise in Overweight and Obese Males and Females?
KR20230124538A (ko) 운동 없이 근육량, 근력 및 근육 기능을 개선하기 위한 β-하이드록시-β-메틸부티레이트(HMB)의 조성물 및 사용 방법
Demaison et al. Is there an ‘obesity paradox’of cardiac survival in heart disease? A perspective from experimental laboratory studies
Hogwood et al. Sex Differences in the Effects of Inorganic Nitrate Supplementation On Exercise Economy 1 and Endurance Capacity in Healthy Young Adults 2
Lee et al. b-hydroxy-b-methylbutyrate (HMB) Improves Relative Grip Strength and Sensorimotor Function in Middle aged and Old Rats: 2856: Board# 207 June 4 3: 30 PM-5: 00 PM
Contreras Fat metabolism and acute resistance exercise in trained women
HK1170632B (en) Improved method of administering beta-hydroxy-beta-methylbutyrate (hmb)
HK1170632A (en) Improved method of administering beta-hydroxy-beta-methylbutyrate (hmb)

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: METABOLIC TECHNOLOGIES, LLC

Free format text: FORMER OWNER(S): METABOLIC TECHNOLOGIES, LLC; TSI, INC.